https://www.investing.com/news/pro/clsa-downgrades-resmed-rmdau-to-outperform-2-high-nearterm-expectations-may-detract-from-longterm-tailwinds-432SI-2872386

https://www.investing.com/news/pro/macquarie-reiterates-outperform-rating-on-resmed-432SI-2872002

ResMed Inc. with ticker code (RMD) have now 6 analysts covering the stock. The analyst consensus points to a rating of ''Buy''. The target price ranges between 276 and 204 with the average target price sitting at 244.33. With the stocks previous close at 240.85 this would indicate that there is a potential upside of 1.4%. There is a 50 day moving average of 221.22 and the 200 day MA is 235.33. The company has a market cap of $35,505m. Visit the company website at: https://www.resmed.com [stock_market_widget type="chart" template="basic" color="green" assets="RMD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,018m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

ResMed Inc (NYSE: RMD ) posted Q4 sales of $914.7 million , +4% Y/Y (+8% on a constant currency basis), beating the consensus of $912.97 million. Adjusted EPS reached $1.49, up from $1.35 a year ago. The company also increased its quarterly dividend to $0.44 from $0.42 per share. Keybanc reiterates the Overweight rating and price target of $276. The analyst says that after resetting near-term supply chain expectations, visibility appears to … Full story available on Benzinga.com

ResMed (RMD) traded lower Friday despite posting better than expected financials for Q4 fiscal 2022 after JPMorgan and RBC Capital Markets moved to downgrade the dual-listed…

Tuesday marks the last chance for investors to receive the next dividend payout from ResMed (NYSE: RMD ). What''s Happening The company announced on Thursday that it would pay shareholders a quarterly dividend of 44 per share. On Wednesday, ResMed will go ex-dividend, meaning the stock will trade lower to reflect that payout. In other words, … Full story available on Benzinga.com

https://www.investing.com/news/pro/jpmorgan-downgrades-resmed-to-neutral-432SI-2871436

ResMed (RMD) declares $0.44/share quarterly dividend, 4.8% increase from prior dividend of $0.42. Forward yield 0.73% Payable Sept. 22; for shareholders of record Aug. 18; ex-div Aug. 17.

https://www.investing.com/news/pro/resmed-pt-raised-to-222-at-morgan-stanley-432SI-2870988

Resmed, Inc. (NYSE:NYSE:RMD) Q4 2022 Earnings Conference Call August 11, 2022, 16:30 ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Michael Farrell - CEO &…

The following slide deck was published by ResMed Inc.

RMD earnings call for the period ending June 30, 2022.

ResMed (RMD) is scheduled to announce Q4 earnings results on Thursday, August 11th, after market close.The consensus EPS Estimate is $1.46 (+8.1% Y/Y) and the consensus Revenue Estimate…

DIS, ILMN, AIG, TDG, SYY, D, EMR, WELL, RMD, and IFF all have company earnings announcements this week. This summary looks back at their… Continue reading on Databyte Financial Insights »

ResMed Inc. with ticker code (RMD) now have 6 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 276 and 204 and has a mean target at 244.33. Now with the previous closing price of 238.7 this indicates there is a potential upside of 2.4%. There is a 50 day moving average of 217.5 while the 200 day moving average is 235.98. The company has a market capitalisation of $35,372m. You can visit the company''s website by visiting: https://www.resmed.com [stock_market_widget type="chart" template="basic" color="green" assets="RMD" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $36,206m based on the market concensus. ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.

ResMed''s (NYSE: RMD ) short percent of float has risen 14.44% since its last report. The company recently reported that it has 1.50 million shares sold short , which is 1.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price … Full story available on Benzinga.com

This year has been a particularly rough year for growth stocks. The severe macroeconomic climate has led to a broad risk-off investment sentiment, forcing investors toward defensive plays. On the positive side, there are plenty of opportunities to buy well-known growth names at discounted valuations. For example, the Vanguard Growth ETF (NYSEARCA: VUG ), one of the largest growth exchange-traded funds (ETFs), is down 31% year-to-date (YTD), compared to a 21% decline for the S&P 500 index. Meanwhile, the iShares Russell 1000 Growth ETF (NYSEARCA: IWF ) has declined 28% in 2022, twice the 14% dip for its counterpart, the iShares Russell 1000 Value ETF (NYSEARCA: IWD ). The 7 Worst Stocks to Buy in a Bear Market However, history tells us high-growth stocks constitute a smart place for long-term investors to allocate a portion of their investment portfolio. With that information, here are seven growth stocks for Q3. Ticker Company Current Price ADI Analog Devices $145 NET Cloudflare $42.71 FAST Fastenal $49.77 LRCX Lam Research $421.50 RMD Resmed $211.55 SHOP Shopify $31.52 TER Teradyne $89.19 Analog Devices (ADI) Semiconductor play Analog Devices (NASDAQ: ADI ) manufactures integrated circuits that process high-performance analog and digital signals.

Hub24 and ResMed are among this broker''s favourites. The post Broker rates these 2 top ASX 200 shares as buys in July appeared first on The Motley Fool Australia .

The Pistoia Alliance is announcing that it has successfully completed a proof of concept (PoC) on the digital transfer via cloud of analytical High Performance Liquid Chromatography (HPLC) methods, proving it is possible to move analytical methods securely between two different vendors and Chromatography Data Systems (CDS) vendors with ease. This PoC delivers on a…

Analog Devices, Inc. announced the industry’s first high-resolution, industrial quality, indirect Time-of-Flight (iToF) module for 3D depth sensing and vision systems.

Many automotive and industrial touch HMI designers are looking to merge the benefits of a mechanical rotary encoder input with the flexibility of modern multi-touch displays. Microchip Technology Inc. announces the maXTouch Knob on Display (KoD) controller as the first automotive-grade touchscreen controller family to natively support the detection and reporting of capacitive rotary encoders, as well as […]

Bourns, Inc. announced the expansion of the Company’s POWrFuse High-Power Fuse product family. The two new POWrFuse models PF-F and PF-M series are high power rating industrial fuse links specially designed to meet the UL 248-13 semiconductor (aR) standard. These high-power fuses are excellent solutions to help protect sensitive power semiconductor devices against overcurrent events in a […]

Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during […]